News

A scheduled meeting of the FDA's Oncologic Drugs Advisory Committee supported the indication of pexidartinib as a treatment for adult patients with symptomatic tenosynovial giant cell tumor. The panel voted 12 to 3 in favor of the CSF1R inhibitor. 

In an interview with&nbsp;<em>Targeted Oncology</em>, Banu Arun, MD, discussed the role of genetic testing in patients with metastatic breast cancer. She highlighted the importance of identifying various mutations, including&nbsp;<em>BRCA1/2&nbsp;</em>mutations in light of the approval of PARP inhibitors. In addition, she spoke to how the role of genomic testing is evolving in this field with the development of new targeted agents.

The FDA has granted P-BCMA-101 with an orphan drug designation for the treatment of patients with relapsed and/or refractory multiple myeloma.

Pomalidomide was granted a breakthrough designation by the FDA for use as treatment for both patients with HIV-positive Kaposi sarcoma who have had prior chemotherapy and patients with HIV-negative Kaposi sarcoma.

Ramucirumab monotherapy has received an approval from the FDA for the treatment of&nbsp;patients with hepatocellular carcinoma who have an alpha fetoprotein of &ge;400 ng/mL and have been previously treated with sorafenib.

Jacqueline C. Barrientos, MD, MS,&nbsp;discusses the emerging treatment options for patients with CLL, as well as some of the other strategies being looked at in clinical trials.

According to findings from an exploratory analysis from the phase III IMpower150 trial presented at the 2019 European Lung Cancer Congress, atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with <em>EGFR</em>-positive metastatic nonsquamous non&ndash;small cell lung cancer who have failed on TKI treatment.

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided CRC and highlights recent research on tumor sidedness and its impact on clinical practice.

Elizabeth Kessler, MD, explained to a group of physicians in a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation the treatment considerations and decisions she makes when seeing a patient with prostate cancer in the clinic.

Nicolas Girard, MD,&nbsp;discussed the importance of evaluating durvalumab in a real-world setting. In addition, he highlights other questions that remain unanswered in this area, as well as the role of immunotherapy in patients with NSCLC.

Final results from the phase III CheckMate 498 trial demonstrated that nivolumab in combination with radiation failed to demonstrate a significant improvement in overall survival compared with temozolomide and radiation in patients with newly diagnosed <em>MGMT</em>-unmethylated glioblastoma multiforme.

In topline findings from the phase II DESTINY-BreastO1 study,&nbsp;[fam-] trastuzumab deruxtecan demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine.

Treatment with vaginal cuff brachytherapy plus paclitaxel and carboplatin chemotherapy was not found to be superior to pelvic radiation therapy in patients with high-intermediate and high-risk early-stage endometrial cancer, according to findings from a phase III trial recently published in the <em>Journal of Clinical Oncology</em>.

R. Michael Tuttle, MD, discusses the outcomes from a 2-day interactive meeting which brought together thryoid cancer experts across 4 organizations and 8 countries to discuss the use of radioactive iodine therapy, including the development of 9 principles for the optimal management of patients.

The phase III ASCEND trial has met its primary endpoint, as findings from the study showed that patients with previously treated chronic lymphocytic leukemia had a statistically significant and clinically meaningful improvement in PFS with acalabrutinib compared with the combination of rituximab and either idelalisib or bendamustine.

Patient-reported outcomes from the phase III myeloma X trial suggested that although patients with relapsed multiple myeloma who received salvage autologous stem cell transplantation had an initial reduction in quality of life and experienced a greater impact of adverse events, they had better long-term outcomes compared with patients who received nontransplantation consolidation.

Vofatamab when given as a monotherapy or in combination with docetaxel was well tolerated and had no long-term safety issues in 55 patients with metastatic urothelial cancer who had failed platinum-based chemotherapy, according to the results of a phase II expansion study.

The FDA has granted a fast track designation to a novel CCR5 antagonist, leronlimab (PRO 140), for use in combination with carboplatin to treat patients with CCR5-positive metastatic triple-negative breast cancer.

Mirvetuximab soravtansine, an antibody-drug conjugate, led to a favorable benefit-risk profile in patients with&nbsp;folate receptor alpha&ndash;positive ovarian cancer according to a comprehensive analysis of the phase III FORWARD trial.

Andre Goy, MD,&nbsp;highlighted major controversies being investigated in the field of MCL in terms of patient subgroups and optimal management of each subpopulation.

In a preliminary analysis of a phase II trial, the radiolabeled small molecule, ¹⁷⁷LuPSMA-617, demonstrated a biochemical progression-free survival of 4 months in a cohort of 64 men with metastatic castrate-resistant prostate cancer.

A phase III clinical trial evaluating&nbsp;cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with previously untreated advanced renal cell carcinoma has been initiated, according to Exelixis, the developer of cabozantinib.

In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author&nbsp;Ghanshyam Yadav, MD.

Ado-trastuzumab emtansine has been approved by the FDA for use as an adjuvant treatment option for patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment with&nbsp;trastuzumab and chemotherapy.

The combination of atezolizumab and cobimetinib failed to demonstrate a significant benefit compared with regorafenib in a phase III study of heavily pretreated patients with advanced colorectal cancer.

In an interview with Targeted Oncology, Alexander E. Perl, MD,&nbsp;discussed the final results from the ADMIRAL trial and the impact these results have on practice.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, discussed the diagnostic workup and treatment considerations he makes when seeing a patient with Hodgkin lymphoma in the clinic.

The NCODA Patient Satisfaction Surveys&nbsp;aim to evaluate overall satisfaction with the pharmacy model from which patients receive therapy, convenience, timing to receive drug, interaction with staff, and financial assistance if available.

Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line&nbsp;treatment of adult patients with <em>IDH1</em>-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are &ge;75 years old or are ineligible to receive intensive chemotherapy.

A new single-center report has found that the results of next-generation sequencing&ndash;based molecular profiling for non&ndash;GI stromal tumor sarcomas provided information used to effectively guide clinical management.